Seminars in Oncology
Volume 33 , Pages 22-27 , June 2006

Anthracycline-Induced Cardiotoxicity in Adult Hematologic Malignancies

  • S.A. Johnson

      Affiliations

    • Dr Johnson has served as a speaker for Chiron Biopharmaceuticals.
    • Corresponding Author InformationAddress reprint requests to S.A. Johnson, MB, BS, Taunton and Somerset Hospital, Musgrove Park, TA1 5DA Taunton, UK.

References 

  1. Johnson SA , Richardson DS . Anthracyclines in haematology (Pharmacokinetics and clinical studies) . Blood Rev . 1998;12:52–71
  2. Yates J , Glidewell O , Wiernik P , et al.  Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia (A CALGB study) . Blood . 1982;60:454–462
  3. Rowe JM , Tallman MS . Intensifying induction therapy in acute myeloid leukemia (Has a new standard of care emerged?) . Blood . 1997;90:2121–2126
  4. The AML Collaborative Group . A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia . Br J Haematol . 2006;103:100–109
  5. Bonadonna G , Monfardini S , De LM , et al.  Phase I and preliminary phase II evaluation of adriamycin (NSC 123127) . Cancer Res . 1970;30:2572–2582
  6. Coltman CA . Adriamycin (NSC-123127) in the treatment of lymphomas (Southwest Oncology Group Studies) . Cancer Chemother Rep . 1975;6:375–380
  7. Bonadonna G , DeLena M , Monfardini S , et al.  Combination usage of adriamycin (NSC-123127) in malignant lymphomas . Cancer Chemother Rep . 1975;6:381–388
  8. Barlogie B , Smith L , Alexanian R . Effective treatment of advanced multiple myeloma refractory to alkylating agents . N Engl J Med . 1984;310:1353–1356
  9. Minotti G , Menna P , Salvatorelli E , et al.  Anthracyclines (Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity) . Pharmacol Rev . 2004;56:185–229
  10. Lefrak EA , Pitha J , Rosenheim S , et al.  A clinicopathologic analysis of adriamycin cardiotoxicity . Cancer . 1973;32:302–314
  11. Von Hoff DD , Layard MW , Basa P , et al.  Risk factors for doxorubicin-induced congestive heart failure . Ann Intern Med . 1979;91:710–717
  12. Swain SM , Whaley FS , Ewer MS . Congestive heart failure in patients treated with doxorubicin (A retrospective analysis of three trials) . Cancer . 2003;97:2869–2879
  13. Lipshultz S , Rifai N , Sallan SE , et al.  Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury . Circulation . 1997;96:2641–2648
  14. Shan K , Lincoff AM , Young JB . Anthracycline-induced cardiotoxicity . Ann Intern Med . 1996;125:47–58
  15. Limat S , Demesmay K , Voillat L , et al.  Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin’s lymphoma . Ann Oncol . 2003;14:277–281
  16. Anderlini P , Benjamin RS , Wong FC , et al.  Idarubicin cardiotoxicity (A retrospective study in acute myeloid leukemia and myelodysplasia) . J Clin Oncol . 1995;13:2827–2834
  17. Nousiainen T , Jantunen E , Vanninen E , et al.  Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients . Br J Cancer . 2002;86:1697–1700
  18. Kremer LC , van Dalen EC , Offringa M , et al.  Anthracycline-induced clinical heart failure in a cohort of 607 children (Long-term follow-up study) . J Clin Oncol . 2001;19:191–196
  19. Lipshultz SE , Colan SD , Gelber RD , et al.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood . N Engl J Med . 1991;324:808–815
  20. Aviles A , Arevila N , az Maqueo JC , et al.  Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin’s disease in adults . Leuk Lymphoma . 1993;11:275–279
  21. Weinstein DM , Mihm MJ , Bauer JA . Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice . J Pharmacol Exp Ther . 2000;294:396–401
  22. Hequet O , Le QH , Moullet I , et al.  Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults . J Clin Oncol . 2004;22:1864–1871
  23. Brockstein BE , Smiley C , Al-Sadir J , et al.  Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer (Prognostic factors) . Bone Marrow Transplant . 2000;25:885–894
  24. Robin M , Guardiola P , Dombret H , et al.  Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission (Risk factors for long-term morbidity and mortality) . Bone Marrow Transplant . 2003;31:877–887
  25. Stevenson LW . Tailored therapy to hemodynamic goals for advanced heart failure . Eur J Heart Fail . 1999;1:251–257
  26. Jensen BV , Skovsgaard T , Nielsen SL . Functional monitoring of anthracycline cardiotoxicity (A prospective, blinded, long-term observational study of outcome in 120 patients) . Ann Oncol . 2002;13:699–709
  27. Stewart AL , Greenfield S , Hays RD , et al.  Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study . JAMA . 1989;262:907–913
  28. Dracup K , Walden JA , Stevenson LW , et al.  Quality of life in patients with advanced heart failure . J Heart Lung Transplant . 1992;11:273–279
  29. Juenger J , Schellberg D , Kraemer S , et al.  Health related quality of life in patients with congestive heart failure (Comparison with other chronic diseases and relation to functional variables) . Heart . 2002;87:235–241
  30. Duggan DB , Petroni GR , Johnson JL , et al.  Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease (Report of an intergroup trial) . J Clin Oncol . 2003;21:607–614
  31. Desikan R , Jagannath S , Richardson P , et al.  Multiple myeloma and otherplasma cell dyscrasias. In:  Pazdur R ,  Coia LR ,  Hoskins WJ ,  Wagman J editor. Cancer Management (A Multidisciplinary Approach.). New York: Oncology Group; 2003;p. 727–746

PII: S0093-7754(06)00209-0

doi: 10.1053/j.seminoncol.2006.04.021

Seminars in Oncology
Volume 33 , Pages 22-27 , June 2006

Article Tools

* Image Usage & Resolution